Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension

American Journal of Hypertension

Volumn 21, Issue 5, 2008, Pages 546-552

  Xi, Gui Lin ^a   Cheng, Jin Wei ^b   Lu, Guo Cai ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LOSARTAN; PLACEBO; TELMISARTAN;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 42549085390     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.30     Document Type: Article

References (25)

1. Lawes CM, Bennett DA, Lewington S, Rodgers A. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med 2002; 2:355-368.
2. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370:591-603.
3. Vongpatanasin W. Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction. J Clin Hypertens 2007; 9(Suppl 4):11-15.
4. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45:907-913.
5. Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2000; 2:402-411.
6. Carr AA, Prisant LM. Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol 1996; 36:3-12.
7. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61:1501-1529.
8. Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000; 20:130-139.
9. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904-912.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
13. Mallion J, Siche J, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:657-664.
14. Fogari R, Mugellini A, Zoppi A, Derosa G, Rinaldi A, Fogari E, Vanasia A, Preti P. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Curr Ther Res Clin Exp 2002; 63:1-14.
15. Fang ZG, Lin HS. Effect of telmisartan on essential hypertension and left ventricular hypertrophy. Xiandai Shiyong Yixue 2003; 15:80-82.
16. Samra SS, Dongre N, Ballary C, Desai A. Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. J Indian Med Assoc 2003; 101:327-328.
17. Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8:111-117.
18. Ding PY, Chu KM, Chiang HT, Shu KH. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract 2004; 58(Suppl):16-22.
19. Lee YT, Lee CM, Lin CS, Sheu SH, Kuo WK, Tsai CW, Huang LC, Huang HC, Wang JS, Tseng WK. A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients. Int J Clin Pract 2004; 58(Suppl):40-45.
20. Zhu JR, Bai J, Cai NS, Tang B, Fan WH, Guo JZ, Ke YN, Guo JX, Sheng LH, Lu ZY, Cheng NN. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract 2004; 58(Suppl):46-49.
21. Chen L, You X-H, Pan J-W, Qin Y-W, Bi W-S, Zheng X. Therapeutic effects of telmisartan on patients with mild-to-moderate essential hypertension and its safety. Yaoxue Fuwu Yu Yanjiu 2005; 5:35-37.
22. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GMC. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4:6.
23. Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 2007; 30:49-53.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
25. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003; 5:58-63.